| Literature DB >> 31098757 |
Chelang'at Sitonik1,2, L M Suresh1, Yoseph Beyene1, Michael S Olsen1, Dan Makumbi1, Kiplagat Oliver2, Biswanath Das1, Jumbo M Bright1, Stephen Mugo1, Jose Crossa3, Amsal Tarekegne4, Boddupalli M Prasanna5, Manje Gowda6.
Abstract
KEY MESSAGE: Analysis of the genetic architecture of MCMV and MLN resistance in maize doubled-haploid populations revealed QTLs with major effects on chromosomes 3 and 6 that were consistent across genetic backgrounds and environments. Two major-effect QTLs, qMCMV3-108/qMLN3-108 and qMCMV6-17/qMLN6-17, were identified as conferring resistance to both MCMV and MLN. Maize lethal necrosis (MLN) is a serious threat to the food security of maize-growing smallholders in sub-Saharan Africa. The ability of the maize chlorotic mottle virus (MCMV) to interact with other members of the Potyviridae causes severe yield losses in the form of MLN. The objective of the present study was to gain insights and validate the genetic architecture of resistance to MCMV and MLN in maize. We applied linkage mapping to three doubled-haploid populations and a genome-wide association study (GWAS) on 380 diverse maize lines. For all the populations, phenotypic variation for MCMV and MLN was significant, and heritability was moderate to high. Linkage mapping revealed 13 quantitative trait loci (QTLs) for MCMV resistance and 12 QTLs conferring MLN resistance. One major-effect QTL, qMCMV3-108/qMLN3-108, was consistent across populations for both MCMV and MLN resistance. Joint linkage association mapping (JLAM) revealed 18 and 21 main-effect QTLs for MCMV and MLN resistance, respectively. Another major-effect QTL, qMCMV6-17/qMLN6-17, was detected for both MCMV and MLN resistance. The GWAS revealed a total of 54 SNPs (MCMV-13 and MLN-41) significantly associated (P ≤ 5.60 × 10-05) with MCMV and MLN resistance. Most of the GWAS-identified SNPs were within or adjacent to the QTLs detected through linkage mapping. The prediction accuracy for within populations as well as the combined populations is promising; however, the accuracy was low across populations. Overall, MCMV resistance is controlled by a few major and many minor-effect loci and seems more complex than the genetic architecture for MLN resistance.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31098757 PMCID: PMC6647133 DOI: 10.1007/s00122-019-03360-x
Source DB: PubMed Journal: Theor Appl Genet ISSN: 0040-5752 Impact factor: 5.699
Fig. 1Phenotypic distribution of disease severity and the AUDPC values for MCMV and MLN on a 1–9 scale in three DH populations, combined DH populations, and the IMAS panel
Means, ranges and components of variance for DS and area under disease progress curve (AUDPC) for maize inbred lines from IMAS association panel and three DH populations inoculated with MCMV and MLN viruses
| Trait | Mean (range) |
|
|
|
|
|---|---|---|---|---|---|
| CML550 X CML504 (DH pop1) | |||||
| MCMV-DS | 3.98 (2.92–4.92) | 0.31** | 0.13** | 0.39 | 0.74 |
| MCMV-AUDPC | 191.10 (136.00–232.90) | 726.36** | 379.76** | 541.94 | 0.77 |
| MLN-DS | 6.14 (4.19–7.96) | 0.77** | 0.00 | 0.39 | 0.80 |
| MLN-AUDPC | 172.6 (118.90–222.70) | 598.53** | 0.00 | 188.41 | 0.86 |
| CML550 X CML511 (DH pop2) | |||||
| MCMV-DS | 6.11 (4.97–7.19) | 0.10* | 0.04** | 0.23 | 0.57 |
| MCMV-AUDPC | 293.20 (263.9–318.5) | 59.84* | 42.26* | 436.74 | 0.31 |
| MLN-DS | 6.91 (5.70–8.61) | 0.62** | 0.00 | 0.31 | 0.80 |
| MLN-AUDPC | 196.30 (160.60–250.90) | 453.92** | 0.00 | 202.81 | 0.82 |
| CML550 X CML494 (DH pop3) | |||||
| MCMV-DS | 4.60 (3.83–5.20) | 0.09** | 0.00 | 0.24 | 0.43 |
| MCMV-AUDPC | 222.48 (185.90–241.30) | 197.71** | 0.00 | 323.93 | 0.55 |
| MLN-DS | 4.50 (3.15–5.30) | 0.18** | 0.08** | 0.32 | 0.73 |
| MLN-AUDPC | 120.78 (85.33–147.98) | 164.63** | 39.66** | 198.38 | 0.81 |
| Combined DH populations | |||||
| MCMV-DS | 4.42 (3.47–5.33) | 0.21** | 0.11** | 0.36 | 0.78 |
| MCMV-AUDPC | 217.20 (168.40–256.40) | 379.82** | 274.28** | 476.56 | 0.82 |
| MLN-DS | 5.28 (3.85–7.18) | 0.36** | 0.09** | 0.34 | 0.89 |
| MLN-AUDPC | 148.24 (103.79–202.95) | 312.48** | 45.27** | 199.13 | 0.92 |
| IMAS AM panel | |||||
| MCMV-DS | 4.37 (3.30–5.60) | 0.34** | 0.39** | 0.80 | 0.56 |
| MCMV-AUDPC | 170.43 (139.50–208.80) | 310.57** | 352.30** | 562.51 | 0.60 |
| MLN-DS | 4.96 (2.48–7.29) | 0.94** | 0.31** | 1.66 | 0.71 |
| MLN-AUDPC | 155.73 (40.37–240.81) | 803.27** | 294.99** | 1180.48 | 0.73 |
*, **Significance at P < 0.05 and P < 0.01, respectively
Detection of QTL associated with resistance to MCMV and MLN (based on disease severity and AUDPC value), their physical positions and genetic effects in three DH populations
| Virus | Trait | QTL name | Chr | Position (cM) | LOD | PVE (%) | Add | Total PVE (%) | QTL confidence interval | Favorable allele from | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Left M | Right M | ||||||||||
| CML550 X CML504 DH pop | |||||||||||
| MCMV | Disease severity | 1 | 191 | 6.24 | 4.65 | − 0.10 | 67.89 | S1_80964123 | S1_84413650 | CML504 | |
| 2 | 98 | 4.16 | 2.92 | − 0.08 | S2_95377918 | S2_96811777 | CML504 | ||||
| 3 | 39 | 43.97 | 49.87 | 0.34 |
|
| CML550 | ||||
| 5 | 51 | 2.76 | 1.93 | 0.07 | S5_131040959 | S5_147478496 | CML550 | ||||
| 9 | 82 | 3.89 | 2.72 | − 0.08 | S9_136073220 | S9_133546700 | CML504 | ||||
| AUDPC | 1 | 88 | 3.54 | 4.76 | − 5.11 | 72.80 | S1_191199656 | S1_8038925 | CML504 | ||
| 1 | 185 | 3.28 | 1.96 | − 3.25 | S1_75202736 | S1_76633047 | CML504 | ||||
| 2 | 89 | 4.27 | 2.57 | − 3.73 | S2_148564919 | S2_144479730 | CML504 | ||||
| 3 | 39 | 53.91 | 58.70 | 17.81 |
|
| CML550 | ||||
| 8 | 105 | 4.17 | 4.22 | − 4.78 | S8_149983936 | S8_169645402 | CML504 | ||||
| MLN | Disease severity | 3 | 38 | 20.81 | 21.43 | 0.35 | 60.63 |
|
| CML550 | |
| 3 | 72 | 11.23 | 15.24 | 0.29 |
|
| CML550 | ||||
| 4 | 105 | 3.88 | 3.34 | − 0.14 | S4_123186378 | S4_96312333 | CML504 | ||||
| 6 | 183 | 3.67 | 3.53 | 0.14 |
|
| CML550 | ||||
| AUDPC | 3 | 38 | 25.34 | 23.73 | 10.56 | 65.92 |
|
| CML550 | ||
| 3 | 72 | 9.46 | 11.02 | 7.21 |
|
| CML550 | ||||
| 4 | 105 | 4.15 | 3.06 | − 3.80 | S4_123186378 | S4_96312333 | CML504 | ||||
| 6 | 188 | 3.75 | 2.78 | 3.62 |
|
| CML550 | ||||
| 7 | 61 | 3.08 | 2.29 | − 3.28 | S7_149357653 | S7_139724362 | CML504 | ||||
| 7 | 273 | 2.63 | 4.25 | − 4.47 | S7_995619 | S7_2133516 | CML504 | ||||
| CML550 X CML511 DH pop | |||||||||||
| MCMV | Disease severity | 2 | 205 | 3.44 | 11.14 | 0.05 | 28.81 |
|
| CML550 | |
| 3 | 229 | 4.87 | 15.70 | 0.07 |
|
| CML550 | ||||
| AUDPC | 3 | 223 | 2.75 | 10.86 | 2.99 | 10.29 |
|
| CML550 | ||
| MLN | Disease severity | 3 | 228 | 9.74 | 33.00 | 0.19 | 33.15 |
|
| CML550 | |
| AUDPC | 3 | 223 | 7.50 | 26.62 | 9.66 | 26.21 | S3_119322983 | S3_85659716 | CML550 | ||
| CML550 X CML494 DH pop | |||||||||||
| MCMV | Disease severity | 1 | 123 | 4.67 | 9.56 | − 0.06 | 12.45 | S1_296767813 | S1_290856560 | CML494 | |
| 4 | 10 | 3.91 | 30.61 | − 0.16 |
|
| CML494 | ||||
| 7 | 154 | 2.80 | 5.20 | − 0.04 | S7_132165418 | S7_135891516 | CML494 | ||||
| AUDPC | 1 | 123 | 4.73 | 9.72 | − 1.65 | 13.07 | S1_296767813 | S1_290856560 | CML494 | ||
| 4 | 22 | 2.66 | 30.56 | − 3.50 |
|
| CML494 | ||||
| 7 | 137 | 3.60 | 6.71 | − 1.36 | S7_129265174 | S7_132165418 | CML494 | ||||
| MLN | Disease severity | 4 | 88 | 3.64 | 6.55 | − 0.09 | 25.43 | S4_235268661 | S4_230348667 | CML494 | |
| 5 | 200 | 2.75 | 4.06 | − 0.12 | S5_85865774 | S5_135455214 | CML494 | ||||
| 6 | 213 | 6.13 | 9.29 | − 0.11 | S6_93323515 | S6_89823772 | CML494 | ||||
| 7 | 191 | 5.99 | 12.88 | − 0.13 |
|
| CML494 | ||||
| AUDPC | 3 | 169 | 2.81 | 3.75 | 2.25 | 31.99 | S3_28920381 | S3_35353666 | CML550 | ||
| 4 | 88 | 6.46 | 10.66 | − 3.73 |
|
| CML494 | ||||
| 4 | 200 | 3.34 | 4.65 | − 2.49 | S4_20053786 | S4_14632354 | CML494 | ||||
| 6 | 214 | 4.82 | 6.70 | − 2.95 |
|
| CML494 | ||||
| 7 | 186 | 7.16 | 13.57 | − 4.21 |
|
| CML494 | ||||
Markers with bold letters are the QTL consistent across DS and AUDPC values
LOD logarithm of odds; Add additive effect; PVE phenotypic variance explained
Analysis of trait-associated markers, allele substitution (α) effects, and the total phenotypic variance (R2) of the joint linkage association mapping based on combined three DH populations
| MCMV | QTL name | Chr | Position (Mbp) | Disease severity | AUDPC | ||||
|---|---|---|---|---|---|---|---|---|---|
| PVE (%) | PVE (%) | ||||||||
| S1_10960822 | 1 | 10.961 | – | – | – | − 6.21 | 3.01E − 24 | 9.60 | |
| S1_71020191 | 1 | 71.020 | − 0.10 | 2.23E − 11 | 4.40 | – | – | – | |
| S2_38977357 | 2 | 38.977 | – | – | – | − 3.57 | 2.07E − 09 | 3.10 | |
| S2_111135899 | 2 | 111.136 | − 0.08 | 1.62E − 08 | 3.10 | – | – | – | |
| S2_189579989 | 2 | 189.580 | 0.04 | 3.81E − 02 | 0.40 | 11.95 | 3.04E − 45 | 20.30 | |
| S3_108706910 | 3 | 108.707 | 0.31 | 7.87E − 73 | 41.60 | – | – | – | |
| S3_116124132 | 3 | 116.124 | 0.06 | 1.62E − 03 | 0.90 | – | – | – | |
| S3_149234811 | 3 | 149.235 | – | – | – | 2.25 | 3.39E − 04 | 1.10 | |
| S3_196142479 | 3 | 196.142 | − 0.05 | 4.82E − 04 | 1.10 | – | – | – | |
| S4_163779660 | 4 | 163.780 | – | – | – | − 1.27 | 2.97E − 03 | 0.80 | |
| S5_133915065 | 5 | 133.915 | – | – | – | 2.41 | 1.48E − 03 | 1.20 | |
| S5_210676383 | 5 | 210.676 | − 0.05 | 3.20E − 03 | 1.10 | – | – | – | |
| S5_213038590 | 5 | 213.039 | 0.06 | 6.34E − 05 | 2.00 | – | – | – | |
| S6_1540161 | 6 | 1.540 | – | – | – | − 5.27 | 1.03E − 08 | 3.90 | |
|
| 6 | 17.166 | 0.19 | 7.73E − 42 | 27.20 | 9.49 | 3.63E − 47 | 29.40 | |
| S7_5784540 | 7 | 5.785 | – | – | – | − 2.16 | 1.73E − 05 | 2.20 | |
| S8_170127444 | 8 | 170.127 | − 0.10 | 1.93E − 14 | 7.70 | – | – | – | |
| S9_41517817 | 9 | 41.518 | – | – | – | − 5.78 | 1.46E − 15 | 7.80 | |
| Total PVE (%) | 0.58 | 0.67 | |||||||
*Chr Chromosome, PVE proportion of phenotypic variance explained
Fig. 2Major QTL for MCMV and MLN resistance in the DH populations. A likelihood of odds (LOD) scan showing the QTLs identified on chromosome 3. Box–whisker plots display the level of disease resistance or severity for different allele combinations at resistance gene loci explaining > 20% of the phenotypic variation for MCMV and MLN as determined by two strongly associated SNP markers
Fig. 3Manhattan plot and Q–Q plots for the GWAS of MCMV and MLN for disease severity and the AUDPC value in the IMAS association mapping panel. The dashed horizontal line in Manhattan plots depicts the significance threshold (P = 5.8 × 10−5). The X-axis indicates the SNP location along the 10 chromosomes, separated by different colors; Y-axis is the − log10 (P observed) for each analysis. Q–Q plots depicts inflation of observed versus expected − log10 (P values) plots for each trait
Chromosomal position and SNPs significantly associated with MCMV disease severity (DS) and area under disease progress curve (AUDPC) detected by SNP-based GWAS in the IMAS association mapping panel
| Trait | SNP-name | Chr | Position (bp) | MCMV | MAF | Minor Allele | Putative candidate gene | Predicted function of candidate gene |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Disease severity | ||||||||
| S1_79444916 | 1 | 79444916 | 7.44E − 07 | 0.08 | 0.02 | GRMZM2G396640 | Uncharacterized protein | |
| S2_47111414 | 2 | 47111414 | 1.63E − 05 | 0.06 | 0.02 | GRMZM2G086971 | GTPase-mediated signal transduction | |
| S5_11490669 | 5 | 11490669 | 9.81E − 06 | 0.07 | 0.48 | GRMZM2G177934 | Copper ion binding | |
| S5_58728012 | 5 | 58728012 | 1.41E − 05 | 0.06 | 0.03 | GRMZM2G098793 | Glycosyltransferase | |
| S6_28146715 | 6 | 28146715 | 5.79E − 05 | 0.06 | 0.24 | GRMZM2G313448 | Uncharacterized protein | |
| S7_167346730 | 7 | 167346730 | 2.03E − 05 | 0.06 | 0.02 | GRMZM2G158130 | Uncharacterized protein | |
| S8_14796196 | 8 | 14796196 | 4.46E − 05 | 0.06 | 0.03 | GRMZM2G139600 | Gamma-glutamyltransferase activity | |
| S10_139328331 | 10 | 139328331 | 3.37E − 05 | 0.06 | 0.02 | GRMZM2G125585 | Unknown | |
| Total R2 | 0.23 | |||||||
| AUDPC value | ||||||||
| S1_79444916 | 1 | 79444916 | 1.07E − 06 | 0.08 | 0.02 | GRMZM2G396640 | Uncharacterized protein | |
| S2_197143379 | 2 | 197143379 | 5.12E − 05 | 0.06 | 0.03 | GRMZM2G151656 | SAUR52-auxin-responsive SAUR family | |
| S3_217571950 | 3 | 217571950 | 5.84E − 05 | 0.06 | 0.10 | GRMZM2G480687 | Response to freezing; G protein-coupled receptor protein signaling pathway | |
| S5_205155934 | 5 | 205155934 | 2.42E − 05 | 0.06 | 0.06 | GRMZM2G090609 | Caleosin-related protein | |
| S7_130133358 | 7 | 130133358 | 5.31E − 05 | 0.05 | 0.07 | AC210027.3_FG003 | Unknown | |
| S8_149982735 | 8 | 149982735 | 5.39E − 05 | 0.06 | 0.47 | GRMZM2G160990 | G protein-coupled receptor protein signaling pathway | |
| Total R2 | 0.21 | |||||||
Fig. 4Box–whisker plots for the accuracy of genomic predictions assessed by fivefold cross-validation. Results are shown for the combined association panel and DH populations (all), the IMAS association panel, the combined DH populations and the three individual DH populations for the MCMV-DS, MCMV-AUDPC, MLN-DS, and MLN-AUDPC scores
Fig. 5Accuracy of genomic predictions for effect estimation in the IMAS association panel and prediction in individual DH populations. Results are shown for the MCMV-DS, MCMV-AUDPC, MLN-DS and MLN-AUDPC scores